The pan-LOX inhibitor PXS-5505 was granted orphan drug designation for myelofibrosis in mid-2020, and trials with this agent have begun in several cancers, including liver and blood; results are not yet available (ClinicalTrials.gov NCT04676529, NCT05109052). Here, LOX is linked to myelofibrosis.